About Lantheus Holdings, Inc.
https://www.lantheus.comLantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
CEO
Brian A. Markison
Compensation Summary
(Year 2017)
ETFs Holding This Stock
Summary
Showing Top 3 of 204
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Truist Securities
Buy
B. Riley Securities
Buy
TD Cowen
Buy
JMP Securities
Market Outperform
Mizuho
Outperform
Goldman Sachs
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:8.6M
Value:$563.89M
BLACKROCK, INC.
Shares:8.27M
Value:$542.23M
VANGUARD GROUP INC
Shares:6.95M
Value:$456.08M
Summary
Showing Top 3 of 509
About Lantheus Holdings, Inc.
https://www.lantheus.comLantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $384.01M ▲ | $178.75M ▲ | $27.77M ▼ | 7.23% ▼ | $0.41 ▼ | $67.74M ▼ |
| Q2-2025 | $378.05M ▲ | $153.04M ▲ | $78.75M ▲ | 20.83% ▲ | $1.15 ▲ | $122.67M ▲ |
| Q1-2025 | $372.76M ▼ | $135.63M ▲ | $72.94M ▲ | 19.57% ▲ | $1.06 ▲ | $114.96M ▲ |
| Q4-2024 | $391.11M ▲ | $134.67M ▲ | $-11.79M ▼ | -3.01% ▼ | $-0.17 ▼ | $21.55M ▼ |
| Q3-2024 | $378.73M | $108.38M | $131.09M | 34.61% | $1.89 | $198.1M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $382.01M ▼ | $2.28B ▲ | $1.16B ▲ | $1.12B ▼ |
| Q2-2025 | $695.57M ▼ | $2.12B ▲ | $949.29M ▲ | $1.17B ▲ |
| Q1-2025 | $938.53M ▲ | $2.06B ▲ | $891.03M ▼ | $1.16B ▲ |
| Q4-2024 | $912.81M ▲ | $1.98B ▼ | $892.33M ▲ | $1.09B ▼ |
| Q3-2024 | $866.39M | $2.05B | $869.92M | $1.18B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $27.77M ▼ | $105.29M ▲ | $-319.47M ▼ | $-99.17M ▼ | $-313.57M ▼ | $94.67M ▲ |
| Q2-2025 | $78.75M ▲ | $87.11M ▼ | $-232.47M ▼ | $-98.41M ▼ | $-242.95M ▼ | $73.73M ▼ |
| Q1-2025 | $72.94M ▲ | $107.56M ▼ | $-63.72M ▼ | $-18.22M ▲ | $25.73M ▼ | $98.84M ▼ |
| Q4-2024 | $-11.79M ▼ | $155.4M ▼ | $-6.6M ▲ | $-101.33M ▼ | $46.43M ▼ | $139.03M ▼ |
| Q3-2024 | $131.09M | $175.06M | $-67.8M | $1.87M | $109.37M | $159.25M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 DEFINITY | $90.00M ▲ | $80.00M ▼ | $80.00M ▲ | $80.00M ▲ |
 License and Royalty Revenues | $0 ▲ | $10.00M ▲ | $0 ▼ | $10.00M ▲ |
 Other Precision Diagnostics | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 Product | $390.00M ▲ | $370.00M ▼ | $370.00M ▲ | $380.00M ▲ |
 PYLARIFY | $270.00M ▲ | $260.00M ▼ | $250.00M ▼ | $240.00M ▼ |
 Radiopharmaceutical Oncology | $270.00M ▲ | $260.00M ▼ | $250.00M ▼ | $240.00M ▼ |
 Strategic Partnerships And Other | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 Techne Lite | $30.00M ▲ | $20.00M ▼ | $20.00M ▲ | $20.00M ▲ |
 Total Precision Diagnostics | $120.00M ▲ | $100.00M ▼ | $120.00M ▲ | $130.00M ▲ |
 Other Radiopharmaceutical Oncology | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Brian A. Markison
Compensation Summary
(Year 2017)
ETFs Holding This Stock
Summary
Showing Top 3 of 204
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Truist Securities
Buy
B. Riley Securities
Buy
TD Cowen
Buy
JMP Securities
Market Outperform
Mizuho
Outperform
Goldman Sachs
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:8.6M
Value:$563.89M
BLACKROCK, INC.
Shares:8.27M
Value:$542.23M
VANGUARD GROUP INC
Shares:6.95M
Value:$456.08M
Summary
Showing Top 3 of 509